PetMed on the Brink as SilverCape Slashes Offer, Citing Board Failures

SINGAPORE – June 29, 2026 – In a dramatic escalation of its campaign against PetMed Express, Inc. (Nasdaq: PETS), activist investor SilverCape Investments has publicly released a revised, and significantly lower, takeover bid of $3.00 per share in cash. The offer, while still a 70% premium over PetMed’s recent trading price, is a sharp reduction from a $4.00 per share proposal made just six months ago—a haircut the investor squarely blames on the pet pharmacy’s deteriorating financial health and what it calls a “broken, ineffective” board of directors.

The public letter from SilverCape, a Singapore-based family office holding a substantial 12% stake in PetMed, paints a grim picture of a company in freefall. It serves as a critical growth signal—or rather, a distress signal—highlighting the severe consequences when leadership fails to navigate market headwinds and shareholder dissent. The move forces a moment of reckoning for PetMed’s board, led by Chair and Interim CEO Leslie C.G. Campbell, putting them under immense pressure to either engage with the offer or present a viable alternative to stop the bleeding.

A Cascade of Crises

SilverCape’s central argument is that PetMed Express is no longer viable as a public company. The evidence, drawn directly from PetMed’s own financial disclosures, is compelling. The company’s stock price has cratered from a high of $32.30 in July 2021 to a mere $1.76 as of last week, wiping out nearly all of its market value. This isn't just a market downturn; it's a systemic collapse.

Financial reports for the fiscal year ending March 31, 2026, reveal a business showing signs of systemic failure. Net sales plunged 21.1% to $179.0 million, while the net loss ballooned to a staggering $57.3 million, a massive increase from the $6.3 million loss the prior year. The company is hemorrhaging cash, with its reserves plummeting from $54.7 million to just $21.4 million in a single year. This rapid cash burn led to the most alarming signal of all: a warning in PetMed’s own 10-K filing that its financial condition “may currently and in the future raise substantial doubt as to our ability to continue as a going concern.”

“When a company’s own auditors and management are forced to flag a ‘going concern’ risk, it’s the ultimate red flag for investors,” one market analyst commented. “It validates the activist’s claim that the current path is unsustainable and that a drastic change, such as a sale, is not just an option but a necessity.”

The Governance Gauntlet

Beyond the dismal financials, SilverCape’s letter launches a blistering attack on PetMed’s corporate governance and leadership. The investor points to a “revolving door C-suite,” which has seen two CEOs and two CFOs depart in just two years, creating what SilverCape calls “institutional chaos.”

At the center of the criticism is Board Chair Leslie C.G. Campbell, who also stepped in as Interim CEO. SilverCape highlights her $1.3 million base salary as an outsized sum for a company with a market capitalization that has fallen below $40 million. The investor argues this points to a board that is not aligned with the interests of its long-suffering stockholders. This claim is further substantiated by proxy filings showing that board members and executive officers (excluding the former CEO) own less than 1% of the company’s shares.

Adding to the governance concerns are repeated non-compliance notices from Nasdaq for failing to file financial reports on time and a costly whistleblower investigation. SilverCape alleges the board has also protected itself with “substantially off-market by-law provisions” and weaponized a stockholder rights plan to entrench its position and frustrate accountability. “This isn’t just about poor performance; it’s about a breakdown in fiduciary duty,” Peter Kennedy, Managing Director of SilverCape, stated in his letter. “We call on each member of the Board to carefully consider their duties.”

The Price of Inaction

The most tangible signal of value destruction comes from the timeline of SilverCape’s offers. In December 2025, the investor put a $4.00 per share cash offer on the table. According to PetMed’s own disclosures, it had evaluated proposals ranging from $4.00 to $4.25 per share. The board, however, rejected them, stating it was in the best interests of stockholders to remain independent.

SilverCape vehemently disputes the board’s process, claiming there was no “meaningful engagement” and that PetMed failed to run a “bona fide M&A process” to find a better deal. The result, SilverCape argues, is that the ongoing deterioration has shaved a full dollar per share off its offer price. This $1.00 reduction represents a direct and quantifiable cost of the board’s alleged intransigence, a loss borne entirely by the company’s shareholders.

With the revised $3.00 offer, SilverCape is effectively telling the board and fellow investors that time has run out. The proposal offers immediate liquidity for stockholders trapped in an anemic stock with low trading volume, crystallizing value before it erodes completely. As SilverCape declared in its letter, its proposal is “the only credible option in front of stockholders that can end the ongoing destruction of value.” The board must now respond, knowing that every day of delay could see the company’s remaining value dwindle even further.